Pernix Therapeutics Holdings, Inc. (“Pernix”) (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced financial results for the three and nine months ended September 30, 2011.
For the third quarter of 2011, net revenues increased by 120% to $17.1 million, compared to $7.8 million for the third quarter of 2010. The increase in net revenues was due primarily to higher volume of product sales resulting from the launch of the Company’s new CEDAX product formulation, Natroba, and certain generic products.
Net income for the third quarter of 2011 was $2.0 million, or $0.08 per basic and diluted share, compared to $2.4 million, or $0.10 per basic and diluted share for the third quarter of 2010. Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA, a non-GAAP measure) increased 34% to $3.6 million for the third quarter of 2011, compared to $2.7 million for the third quarter of 2010. See the table at the end of this press release for a reconciliation of EBITDA and adjusted EBITDA to net income.Cooper Collins, President and Chief Executive Officer of Pernix, said, “Pernix continued to deliver strong revenue growth, driven by the new CEDAX 180mg formulation, the launch of Natroba, and additional generic products. Going forward, we believe the Company is in a solid financial position and will continue to grow its branded pediatric and generic businesses. We are also currently evaluating licensing and acquisition opportunities to expand into other therapeutic areas that are expected to further broaden our product portfolio and leverage our business platform.” Selling, general and administrative (“SG&A”) expenses in the third quarter of 2011 increased to $5.4 million, compared to $3.5 million for the third quarter of 2010. The increase was primarily due to higher salaries, bonuses, commissions, incentives and stock compensation expense. The increase in commissions was due to greater gross sales and the higher commission rates paid on sales of Natroba. Depreciation and amortization expense increased to $0.6 million for the third quarter of 2011, compared to $0.3 million for the third quarter of 2010. The increase is due to the amortization under certain acquisition agreements, including CEDAX and Macoven. The Company also recognized $0.1 million in expenses related to its joint venture with SEEK for the development of Theobromine during the third quarter of 2011. The Company recognized an income tax expense of $0.9 million for the third quarter of 2011 and 2010.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV